The Czech Republic has made a small procedural change to its reimbursement applications as national systems begin to absorb the EU Joint Clinical Assessment (JCA) process into everyday practice.
The State Institute for Drug Control (Státní ústav pro kontrolu léčiv, SÚKL) updated its web forms and accompanying guidance in September. Applications to establish or change medicine reimbursement now include a dedicated section asking whether a JCA applies and, if so, whether it has been completed, remains under way or has been discontinued.
The revision does not change Czech reimbursement criteria or create a separate national assessment requirement. SÚKL had already indicated that published JCA reports and the associated EU dossier would feed into Czech reimbursement proceedings, with the European clinical assessment given due consideration within the national process.
The new forms instead make that relationship part of routine administration. Applicants now identify the EU assessment position directly when filing, helping SÚKL connect national reimbursement work with evidence already being assessed or published at European level.
The Czech change is therefore another practical step in the wider integration of JCA into national HTA and reimbursement systems. Its immediate scope is limited to medicines currently covered by mandatory JCA, but the relevance of the filing requirement will grow as the EU framework progressively expands.
Source: State Institute for Drug Control, SÚKL
Link: Aktualizace webových formulářů pro podání žádosti o stanovení nebo změnu výše a podmínek úhrady léčivých přípravků (Update of web forms for applications to establish or change the amount and conditions of reimbursement for medicinal products)
Date: 11 September 2026
Source: State Institute for Drug Control, SÚKL
Link: CAU-04 verze 10 – Pokyny pro vyplnění žádosti o stanovení výše a podmínek úhrady / maximální ceny výrobce / maximální ceny výrobce a výše a podmínek úhrady léčivého přípravku (CAU-04 version 10 – Instructions for completing an application to establish reimbursement conditions, maximum manufacturer price, or both)
Date: 9 September 2026
